Core Viewpoint - The company, Xianruida Medical-B (06669), has received approval from the National Medical Products Administration of China for its controllable mechanical detachable fiber spring coil, which is designed for embolization of peripheral vascular aneurysms, arteriovenous malformations, and arteriovenous fistulas [1] Product Details - The product features a controllable release mechanism that ensures a stable and precise deployment of the spring coil, enhancing operational controllability and safety [1] - It offers both 2D and 3D structural options, allowing for broad adaptability to clinical needs [1] Market Strategy - The company plans to initiate marketing activities in China at an appropriate time following the product approval [1]

Core Viewpoint - The company, Xianruida Medical-B (06669.HK), has received registration approval from the National Medical Products Administration of China for its controllable mechanical embolization spring coil, which is designed for peripheral vascular applications [1] Group 1: Product Details - The product is intended for the embolization of peripheral vascular aneurysms, arteriovenous malformations, and arteriovenous fistulas [1] - It features a controllable release mechanism that ensures a stable and precise deployment of the spring coil, enhancing operational control and safety [1] - The product is available in both 2D and 3D structures, allowing for broad adaptability to clinical needs [1] Group 2: Market Strategy - The company plans to initiate marketing activities in China at an appropriate time following the approval [1]

Core Insights - The company reported double-digit growth in both revenue and profit for the first half of 2025, driven by an aging population and increasing oral health awareness [1] - Continuous technological innovation and digital transformation have been key strategies for product upgrades and market expansion [1] Revenue and Profit Growth - The company achieved a revenue of 486 million yuan, representing a year-on-year increase of 17.22%, and a net profit attributable to shareholders of 92 million yuan, up 19.86% [2] - Revenue from oral repair materials reached 358 million yuan, with a growth of 19.19%, accounting for 73.74% of total revenue [2] - The gross margin for oral repair materials decreased to 58.20% from 60.36% due to adjustments in discount frameworks to enhance market share [2] Product and Market Development - The digital equipment segment generated 96 million yuan in revenue, a 3.64% increase, making up 19.80% of total revenue [2] - The gross margin for digital equipment improved to 30.50%, an increase of 1.24% year-on-year [2] - The company has launched several new products in orthodontics, implants, prevention, and treatment, enhancing its product portfolio [2] Research and Development Investment - The company invested 28.255 million yuan in R&D, a 36.12% increase, focusing on a comprehensive product development system across the oral industry chain [3] - The synergy between the two main segments, digital equipment and oral repair materials, has improved market competitiveness [3] Market Expansion Strategy - The company is actively expanding into overseas markets, establishing subsidiaries in mature markets like Europe, the US, Japan, and South Korea to enhance brand recognition and customer satisfaction [3] - New emerging markets in Southeast Asia, the Middle East, and Australia are also being targeted for growth in the dental medical device sector [3]

Core Viewpoint - Lepu Medical (300003.SZ) announced that its subsidiary, Sichuan Xingtai Pule Medical Technology Co., Ltd., has received approval from the National Medical Products Administration for its self-developed injectable cross-linked sodium hyaluronate gel, which is intended for use in correcting moderate to severe nasolabial folds [1] Group 1 - The newly approved product is designed for injection into the mid to deep layers of dermal tissue in the nasolabial fold area [1] - This approval enhances the company's product matrix in the dermatology field, indicating a strategic expansion of its offerings [1] - The market performance of the new product post-launch may be influenced by various factors, leading to uncertainty regarding its impact on the company's future performance [1]

证券代码：300003 证券简称：乐普医疗 乐普（北京）医疗器械股份有限公司 投资者关系活动记录表 编号：2025-002 | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活动 | □媒体采访 ■业绩说明会 | | | □新闻发布会 □路演活动 | | 类别 | □现场参观 | | | □其他 | | 参与单位名称及 | | | | 家境内外机构共 名参会人员，详见附件明细 93 141 | | 人员姓名 | | | 时间 | 2025 年 8 月 23 日 | | 地点 | 电话会议 | | 上市公司接待人 | 董事长 蒲忠杰 | | | 财务总监 王泳 | | 员姓名 | 董事会秘书 江维娜 | | | 公司介绍： | | | 各位投资者上午好！感谢大家周末参加公司 2025 半年度业绩说明 | | | 会。乐普经过各种产品的集采大周期，过去数年业绩波动较大，在此 | | | 期间公司也进行了组织架构、管理方法和考核思路的调整，目前组织 | | | 再造已基本完成，业绩也逐步企稳。 | | | 公司半年报收入、利润端同比基本持平，经营性净现金流大幅改 | | | 善，同 ...

Core Viewpoint - Furuya Medical Technology (01696) has launched the PixelPeel safe laser skin rejuvenation treatment to meet the growing demand for safe, effective, and short-recovery skin renewal procedures [1] Group 1: Product Launch - The PixelPeel treatment has been introduced in North America and is planned for gradual global rollout [1] - PixelPeel utilizes clinically recognized gold standard laser energy combined with pixel-level precision and Alma's proprietary MotionSync technology to ensure a safe, uniform, and controllable treatment process [1] Group 2: Target Audience and Benefits - The treatment is suitable for both first-time users and individuals seeking long-term skin maintenance [1] - PixelPeel offers effective clinical results with a short recovery period and is applicable to various skin types [1] Group 3: Market Impact - The company believes that PixelPeel will provide advanced treatment options that meet current market demands, offering a more convenient and efficient skin care experience [1] - The comprehensive application of PixelPeel in Alma Pixel and Alma Hybrid devices aims to expand market coverage and enhance the purchase and usage rates of these devices [1]

公司发布2025年半年报显示，上半年实现营业收入9.14亿元，同比下降0.91%；归母净利润1.54亿元， 同比增长23.47%；扣非净利润1.45亿元，同比增长26.78%。其中第二季度营业收入4.93亿元，同比增长 3.1%；归母净利润8936万元，同比增长3.2%。国际业务收入5.57亿元，同比增长8.33%，国内市场收入 3.56亿元，同比下降12.56%。 8月25日主力资金净流出666.79万元，近五日主力资金累计净流出4630.22万元。 理邦仪器股价报13.13元，较前一交易日下跌0.05元，跌幅0.38%。盘中最高触及13.29元，最低下探 13.05元，成交量为84167手，成交金额1.11亿元。 理邦仪器属于医疗器械板块，主要从事医疗电子设备和体外诊断产品的研发、生产和销售，产品涵盖病 人监护、心电诊断、妇幼健康、超声影像、体外诊断和智慧健康等六大领域。公司持续推进海外制造战 略，并通过智慧医疗为业务赋能。 风险提示：以上信息仅供参考，不构成投资建议。 来源：金融界 ...

公司相信，PixelPeel能为医疗机构及求美者提供符合当下市场需求的先进疗程，带来更便捷、更高效的 肌肤护理体验。PixelPeel全面应用于Alma Pixel及Alma Hybrid设备，开创全新治疗方案，进一步拓展现 有设备系统的市场覆盖范围，并提升设备的采购率与使用率。 复锐医疗科技(01696)发布公告，推出PixelPeel安全激光焕肤治疗方案，旨在满足对安全、有效且恢复期 短的皮肤焕新疗程日益增长的需求，并全面运用在新一代Alma Pixel及Alma Hybrid设备系统中。该方案 已于北美首发，并计划逐步推向全球市场。 PixelPeel运用临床公认的黄金标准激光能量，结合像素级精准度，并搭载Alma专利MotionSync技术，确 保治疗过程安全、均匀且可控，有效改善肌肤纹理、肤色与透亮度。 该方案不仅适合首次接受治疗的求美者，也同样适合进行长期皮肤维养的人群。PixelPeel在提供高效临 床效果的同时，恢复期短，且适用于各类肤质。 ...

Core Viewpoint - The company has launched the PixelPeel™ safe laser skin rejuvenation treatment to meet the growing demand for safe, effective, and short recovery skin renewal procedures, initially introduced in North America with plans for global expansion [1] Group 1: Product Details - PixelPeel™ utilizes clinically recognized gold standard laser energy combined with pixel-level precision and Alma's proprietary MotionSync™ technology to ensure a safe, uniform, and controllable treatment process [1] - The treatment effectively improves skin texture, tone, and brightness, making it suitable for both first-time users and those seeking long-term skin maintenance [1] - The solution offers high clinical efficacy with a short recovery period and is applicable to various skin types [1] Group 2: Market Impact - The company believes that PixelPeel™ will provide advanced treatment options that align with current market demands, offering a more convenient and efficient skin care experience for medical institutions and consumers [1] - The comprehensive application of PixelPeel™ in Alma Pixel™ and Alma Hybrid devices aims to create a new treatment solution, further expanding the market coverage of existing device systems and enhancing their purchase and usage rates [1]

Group 1 - The core point of the article is that Gongdong Medical (SH 605369) held its board meeting on August 25, 2025, to review the semi-annual report for 2025 [1] - Gongdong Medical's revenue composition for the year 2024 is reported as 98.65% from medical devices and 1.35% from other businesses [1] - The current market capitalization of Gongdong Medical is 4.5 billion yuan [2]